Humacyte (HUMA) revenue and earnings history
Humacyte reported revenue of $2.04M for fiscal 2025 (year ended Dec 31, 2025), and net income of −$40.8M.
Revenue and net income, 6 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $2.04M | −$108M | −$40.8M | −$105M | $884K | −$106M | $9.75M | — | — | $50.5M | $35.4M | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Humacyte (HUMA) on OQRO.
Common questions
What was Humacyte's revenue in fiscal 2025?
$2.04M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 27, 2026.
Has Humacyte been profitable?
It reported a net loss in 6 of the years shown (2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$12M in fiscal 2022.
What was Humacyte's free cash flow in fiscal 2025?
−$106M: operating cash flow of −$105M minus capital expenditure of $884K. OQRO calculates free cash flow this way from the two filed lines.
Does Humacyte buy back shares or pay dividends?
Where these figures come from
The SEC’s companyfacts data: every figure Humacyte tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.